4 results
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
The objective of this study is to determine the safe and efficacious dose required to eradicate LGD or HGD in BE, or residual BE after endoscopic removal of early cancer (*therapeutic dose*), using the C2 CryoBalloon 180 Ablation System. *Dose* is…